Pro-Cure is looking to develop and commercialise new therapies for prostate cancer in collaboration with leading pharmaceutical companies operating in the prostate cancer field or with an active interest in cancer stem cell therapies.
Pro-Cure has been engaged in “value development” activities based on molecular biology based target validation and has a growing pipeline of validated targets. It has now embarked on a programme to develop therapeutic candidates against its lead targets. The company is always willing to talk to potential partners interested in entering into a collaborative research partnership or alliance. Pro-Cure is also looking to exploit the commercialisation of research opportunities in other cancers.
